Table 1.
Characteristics of the patients at baseline (n, %).
| Characteristic | Novel anti-HER2 ADCs (n = 73) | T-DM1 (n = 71) | P |
|---|---|---|---|
| Age (year) | .017 | ||
| Median (range) | 48 (25-89) | 42 (25-63) | |
| <50 | 38 (52.1) | 51 (71.8) | |
| ≥50 | 35 (47.9) | 20 (28.2) | |
| Hormone receptor status | .73 | ||
| Positive | 38 (52.1) | 39 (54.9) | |
| Negative | 35 (47.9) | 32 (45.1) | |
| Menopausal status | .006 | ||
| Premenopausal | 35 (47.9) | 50 (70.4) | |
| Postmenopausal | 38 (52.1) | 21 (29.6) | |
| Clinical stage at diagnosis | .941 | ||
| Ⅰ-Ⅲ | 61 (83.6) | 59 (83.1) | |
| Ⅳ | 12 (16.4) | 12 (16.9) | |
| Visceral metastases | .96 | ||
| Yes | 67 (91.8) | 65 (91.5) | |
| No | 6 (8.2) | 6 (8.5) | |
| Metastatic site | |||
| Bone | 41 (56.2) | 40 (56.3) | .983 |
| Liver | 40 (54.8) | 37 (52.1) | .747 |
| Lung | 42 (57.5) | 35 (49.2) | .322 |
| Brain | 20 (27.4) | 19 (26.8) | .932 |
| Number of metastatic sites | .658 | ||
| 1 | 8 (11.0) | 6 (8.5) | |
| 2 | 18 (24.6) | 22 (31.0) | |
| ≥3 | 47 (64.4) | 43 (60.5) | |
| Number of previous lines of anti-HER2 therapy | .760 | ||
| ≤3 | 28 (38.4) | 30 (40.3) | |
| >3 | 45 (61.6) | 41 (57.7) | |
| Previous anti-HER2 therapy | |||
| Trastuzumab | 73 (100.0) | 71 (100.0) | — |
| Trastuzumab + pertuzumab | 58 (79.5) | 12 (16.9) | <.001 |
| Pyrotinib | 73 (100.0) | 30 (42.3) | <.001 |
| Lapatinib | 18 (24.6) | 51 (71.8) | <.001 |
Abbreviations: HER2: human epidermal growth factor receptor 2; ADCs: antibody-drug conjugates; T-DM1: trastuzumab emtansine.